If you are conducting a multicentre, oncology clinical trial at UHN and the study's ethical oversight is being reviewed by the Ontario Cancer Research Ethics Board (OCREB) through Clinical Trials Ontario (CTO), it is important that the Provincial Applicant creates a sub-form to initiate the UHN Centre Application. In doing so, the UHN CTO Rep will be informed of your intention to add UHN as a site and will be available to provide guidance.

Once the Centre Application for UHN has been created, the UHN CTO Rep will contact the designated UHN Principal Investigator (PI) and recommend starting a CAPCR application to obtain Institutional Authorization (IA) at UHN. IA is a UHN site-specific requirement to ensure the study has appropriate oversight. You will receive IA in CAPCR once all the applicable non-REB reviewers (e.g. Grants and Contracts Services, Research Quality Integration, Laboratory Medicine Program, etc.) approve your study. Once you receive approval from each impacted non REB reviewer in CAPCR (in addition to REB approval from OCREB in CTO Stream), you will receive Institutional Authorization (IA) and may begin study activities at UHN.